Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections | Zendy

Giorgos Tatsis | Zendy; G Tsoukalas | Zendy; Georgios Boulbasakos | Zendy; E. Platsouka | Zendy; Maria Anagnostopoulou | Zendy; Maria Pirounaki | Zendy; O. Paniara | Zendy; E. Sioula | Zendy; J. Raptis | Zendy; George Saroglou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections

Author(s) -

Giorgos Tatsis,

G Tsoukalas,

Georgios Boulbasakos,

E. Platsouka,

Maria Anagnostopoulou,

Maria Pirounaki,

O. Paniara,

E. Sioula,

J. Raptis,

George Saroglou

Publication year - 1998

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/41.suppl_2.69

Subject(s) - roxithromycin , clarithromycin , medicine , respiratory tract infections , adverse effect , lower respiratory tract infection , antibacterial agent , gastroenterology , antibiotics , respiratory tract , respiratory system , erythromycin , microbiology and biotechnology , biology , helicobacter pylori

In an open, randomized, parallel group study, the efficacy and tolerance of roxithromycin 300 mg po od was compared with clarithromycin 500 mg po bd in the treatment of 60 patients with lower respiratory tract infections (LRTI). The two groups were well-matched demographically. Fifty patients (25 per group) were clinically evaluable at the end of the study and a satisfactory response was found in 88% of those given roxithromycin and 80% of those given clarithromycin. All had received treatment for a minimum of 3 days. Only one (3.3%) of 30 patients in the roxithromycin group reported adverse events compared with seven (23.3%) of 30 in the clarithromycin group. Thus both roxithromycin and clarithromycin are effective in the treatment of LRTI but roxithromycin is better tolerated (P < 0.05) with the advantage of a once-daily dose.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research